<DOC>
	<DOCNO>NCT01000207</DOCNO>
	<brief_summary>This study identify preferred vaccine dosage ( antigen adjuvant ) schedule ( one two administration ) cell-derived H1N1sw monovalent vaccine healthy children/adolescents base European Medicines Agency 's Committee Medicinal Products Human Use ( EMEA/CHMP ) criterion , safety tolerability .</brief_summary>
	<brief_title>Single-blind , Dose-ranging Study Novel Swine Influenza Virus Vaccine Japanese Pediatric Subjects</brief_title>
	<detailed_description>This multi-center , randomize , single-blind , dose-ranging study . Subjects randomize 1:1 ratio receive either 3.75μg cell-derived H1N1sw vaccine formulate half ( i.e. , half content European-licensed adjuvanted seasonal influenza vaccine ) MF59 adjuvant ( 3.75_halfMF59 ) 7.5μg cell-derived H1N1sw vaccine formulate full MF59 ( 7.5_fullMF59 ) . Subjects inform allocated dos . Two vaccination administer IM three week apart . Subjects vaccine group stratify three age stratum : 6 35 month , 3 8 year 9 19 year . Blood sample collect day 1 ( baseline ) , three week first vaccination ( day 22 ) three week second vaccination ( day 43 ) . Sera test Hemagglutination Inhibition ( HI ) Microneutralization ( MN ) assay . Local systemic reaction collect first week follow injection use Diary Card ( i.e. , day 1 day 7 day 22 day 28 ) . All adverse event ( AE ) , serious adverse event ( SAE ) , AEs lead withdrawal study relate prescription medication collect entire study period .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy Japanese age 6 month 19 year History anaphylaxis , serious vaccine reaction , hypersensitivity vaccine viral proteins excipients Administration adjuvanted influenza vaccine suspect influenza disease within 3 month prior study start Administration vaccine within 4 week prior enrollment expect seasonal influenza vaccine within 1 week History progressive severe neurological disorder</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Influenza A</keyword>
	<keyword>H1N1 subtype</keyword>
	<keyword>Children/adolescent</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Adjuvant</keyword>
</DOC>